Methods to evaluate biliary excretion of drugs in humans: An updated review

被引:106
作者
Ghibellini, Giulia [1 ]
Leslie, Elaine M. [1 ]
Brouwer, Kim L. R. [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC 27599 USA
关键词
bile; excretion; biliary clearance; hepatic transport; hepatobiliary transport;
D O I
10.1021/mp060011k
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
Determining the biliary clearance of drugs in humans is very challenging because bile is not readily accessible due to the anatomy of the hepatobiliary tract. The collection of bile usually is limited to postsurgical patients with underlying hepatobiliary disease. In healthy subjects, feces typically are used as a surrogate to quantify the amount of drug excreted via nonurinary pathways. Nevertheless, it is very important to characterize hepatobiliary elimination because this is a potential site of drug interactions that might result in significant alterations in systemic or hepatic exposure. In addition to the determination of in vivo biliary clearance values of drugs, the availability of in vitro models that can predict the extent of biliary excretion of drugs in humans may be a powerful tool in the preclinical stages of drug development. In this review, recent advances in the most commonly used in vivo methods to estimate biliary excretion of drugs in humans are outlined. Additionally, in vitro models that can be employed to investigate the molecular processes involved in biliary excretion are discussed to present an updated picture of the new tools and techniques that are available to study the complex processes involved in hepatic drug transport.
引用
收藏
页码:198 / 211
页数:14
相关论文
共 157 条
[1]
QUINIDINE REDUCES BILIARY CLEARANCE OF DIGOXIN IN MAN [J].
ANGELIN, B ;
ARVIDSSON, A ;
DAHLQVIST, R ;
HEDMAN, A ;
SCHENCKGUSTAFSSON, K .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1987, 17 (03) :262-265
[2]
ANGGARD E, 1975, CLIN PHARMACOL THER, V17, P258
[3]
Annaert PP, 2001, DRUG METAB DISPOS, V29, P1277
[4]
CEFTRIAXONE - RENAL AND BILIARY-EXCRETION AND EFFECT ON THE COLON MICROFLORA [J].
ARVIDSSON, A ;
ALVAN, G ;
ANGELIN, B ;
BORGA, O ;
NORD, CE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1982, 10 (03) :207-215
[5]
Balani SK, 1997, DRUG METAB DISPOS, V25, P1282
[6]
CLINICAL PHARMACOKINETICS OF THE 3RD GENERATION CEPHALOSPORINS [J].
BALANT, L ;
DAYER, P ;
AUCKENTHALER, R .
CLINICAL PHARMACOKINETICS, 1985, 10 (02) :101-143
[7]
Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins [J].
Ballatori, N ;
Hammond, CL ;
Cunningham, JB ;
Krance, SM ;
Marchan, R .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2005, 204 (03) :238-255
[8]
Clinical pharmacokinetics of quinupristin/dalfopristin [J].
Bearden, DT .
CLINICAL PHARMACOKINETICS, 2004, 43 (04) :239-252
[9]
Fat in the intestine as a regulator of appetite - role of CCK [J].
Beglinger, C ;
Degen, L .
PHYSIOLOGY & BEHAVIOR, 2004, 83 (04) :617-621
[10]
Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes [J].
Blanchard, N ;
Alexandre, E ;
Abadie, C ;
Lavé, T ;
Heyd, B ;
Mantion, G ;
Jaeck, D ;
Richert, L ;
Coassolo, P .
XENOBIOTICA, 2005, 35 (01) :1-15